{"id":21125,"date":"2022-07-06T13:55:05","date_gmt":"2022-07-06T11:55:05","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=21125"},"modified":"2022-07-07T14:00:40","modified_gmt":"2022-07-07T12:00:40","slug":"evaxion-biotech-targeting-gonorrhea","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-targeting-gonorrhea\/","title":{"rendered":"Evaxion Biotech targeting gonorrhea"},"content":{"rendered":"\n<p>Evaxion Biotech recently announced that it has selected the sexually transmitted disease gonorrhea as the second target for the EVX-B2 vaccine candidate, which is based on the EDEN technology platform. Preliminary preclinical results have shown that the AI platform EDEN has demonstrated the ability to identify two promising protective antigens based on very encouraging results. This suggests that EVX-B2 will be able to produce antibodies against this bacterial infection &#8211; minimizing the risk of infection, which affects over one million annually in the US.&nbsp; Evaxion Biotech thus continues to build on its existing strong pipeline, which is an essential element of our investment case, which can be seen here.<\/p>\n\n\n\n<p>Evaxion Biotech is a Danish biotherapeutics company listed in the US that uses AI-based platforms to develop immunotherapies for the treatment of cancer (the PIONEER platform) and infectious diseases, including bacterial (the EDEN platform) and viral (the RAVEN platform). Promising data from the two ongoing clinical programmes EVX-01 (treatment of metastatic melanoma) and EVX-02 (treatment of adjuvant melanoma) will, in our view, pave the way for further catalysts in the near term. We see several benefits from the use of AI-based platforms, which we believe could expand the use of immunotherapies into additional disease areas that we believe will add further value.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1004\" height=\"597\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/image-38.png\" alt=\"\" class=\"wp-image-20973\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/image-38.png 1004w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/image-38-300x178.png 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/image-38-768x457.png 768w\" sizes=\"(max-width: 1004px) 100vw, 1004px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Evaxion Biotech recently announced that it has selected the sexually transmitted disease gonorrhea as the second target for the EVX-B2 vaccine candidate, which is based on the EDEN technology platform. Preliminary preclinical results have shown that the AI platform EDEN has demonstrated the ability to identify two promising protective antigens based on very encouraging results. [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":19819,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[151,29,165],"tags":[126,154],"class_list":["post-21125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-cases","category-investeringscases","category-investment-cases","tag-evaxion-biotech","tag-evaxion-biotech-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evaxion Biotech targeting gonorrhea | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion Biotech targeting gonorrhea | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Evaxion Biotech recently announced that it has selected the sexually transmitted disease gonorrhea as the second target for the EVX-B2 vaccine candidate, which is based on the EDEN technology platform. Preliminary preclinical results have shown that the AI platform EDEN has demonstrated the ability to identify two promising protective antigens based on very encouraging results. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T11:55:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-07T12:00:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank H. Andersen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank H. Andersen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\"},\"author\":{\"name\":\"Frank H. Andersen\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be\"},\"headline\":\"Evaxion Biotech targeting gonorrhea\",\"datePublished\":\"2022-07-06T11:55:05+00:00\",\"dateModified\":\"2022-07-07T12:00:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\"},\"wordCount\":216,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg\",\"keywords\":[\"Evaxion Biotech\",\"Evaxion Biotech\"],\"articleSection\":[\"Company cases\",\"Investeringscases\",\"Investment cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\",\"url\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\",\"name\":\"Evaxion Biotech targeting gonorrhea | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg\",\"datePublished\":\"2022-07-06T11:55:05+00:00\",\"dateModified\":\"2022-07-07T12:00:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg\",\"width\":800,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investeringscases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Selskabscases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/selskabscases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Evaxion Biotech targeting gonorrhea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be\",\"name\":\"Frank H. Andersen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g\",\"caption\":\"Frank H. Andersen\"},\"sameAs\":[\"Zim\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion Biotech targeting gonorrhea | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion Biotech targeting gonorrhea | Kapital Partner A\/S","og_description":"Evaxion Biotech recently announced that it has selected the sexually transmitted disease gonorrhea as the second target for the EVX-B2 vaccine candidate, which is based on the EDEN technology platform. Preliminary preclinical results have shown that the AI platform EDEN has demonstrated the ability to identify two promising protective antigens based on very encouraging results. [&hellip;]","og_url":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2022-07-06T11:55:05+00:00","article_modified_time":"2022-07-07T12:00:40+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg","type":"image\/jpeg"}],"author":"Frank H. Andersen","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Frank H. Andersen","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/"},"author":{"name":"Frank H. Andersen","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be"},"headline":"Evaxion Biotech targeting gonorrhea","datePublished":"2022-07-06T11:55:05+00:00","dateModified":"2022-07-07T12:00:40+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/"},"wordCount":216,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg","keywords":["Evaxion Biotech","Evaxion Biotech"],"articleSection":["Company cases","Investeringscases","Investment cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/","url":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/","name":"Evaxion Biotech targeting gonorrhea | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg","datePublished":"2022-07-06T11:55:05+00:00","dateModified":"2022-07-07T12:00:40+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/06\/Evaxion_FotoPressConnect_White.jpg","width":800,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/evaxion-biotech-gaar-efter-gonore\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investeringscases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/"},{"@type":"ListItem","position":3,"name":"Selskabscases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/selskabscases\/"},{"@type":"ListItem","position":4,"name":"Evaxion Biotech targeting gonorrhea"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be","name":"Frank H. Andersen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g","caption":"Frank H. Andersen"},"sameAs":["Zim"]}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/21125"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=21125"}],"version-history":[{"count":2,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/21125\/revisions"}],"predecessor-version":[{"id":21127,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/21125\/revisions\/21127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/19819"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=21125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=21125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=21125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}